| Record Information |
|---|
| Version | 2.0 |
|---|
| Creation Date | 2009-07-03 22:08:18 UTC |
|---|
| Update Date | 2014-12-24 20:25:35 UTC |
|---|
| Accession Number | T3D2483 |
|---|
| Identification |
|---|
| Common Name | Glipizide |
|---|
| Class | Small Molecule |
|---|
| Description | Glipizide is only found in individuals that have used or taken this drug. It is an oral hypoglycemic agent which is rapidly absorbed and completely metabolized. [PubChem]Sulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin. |
|---|
| Compound Type | - Amide
- Amine
- Drug
- Hypoglycemic Agent
- Metabolite
- Organic Compound
- Synthetic Compound
|
|---|
| Chemical Structure | |
|---|
| Synonyms | | Synonym | | 1-Cyclohexyl-3-({p-[2-(5-methylpyrazinecarboxamido)ethyl]phenyl}sulfonyl)urea | | Aldiab | | CP 28,720 | | CP 28720 | | CP-28,720 | | Digrin | | Dipazide | | Glibenese | | Glibetin | | Glican | | Glidiab | | Glipid | | Glipin | | Glipizida | | GlipizideER | | Glipizidum | | Glix | | Gluco-rite | | Glucolip | | Glucotrol | | Glucotrol XL | | Glucozide | | Glupitel | | Glupizide | | Glyde | | Glydiazinamide | | K 4024 | | Melizide | | Mindiab | | Minidab | | Minidiab | | Minodiab | | N-{4-[beta-(5-methylpyrazine-2-carboxamido)ethyl]benzenesulphonyl}-n'-cyclohexylurea | | Napizide | | Ozidia | | Sucrazide | | Zitrol XR |
|
|---|
| Chemical Formula | C21H27N5O4S |
|---|
| Average Molecular Mass | 445.535 g/mol |
|---|
| Monoisotopic Mass | 445.178 g/mol |
|---|
| CAS Registry Number | 29094-61-9 |
|---|
| IUPAC Name | N-[2-(4-{[(cyclohexylcarbamoyl)amino]sulfonyl}phenyl)ethyl]-5-methylpyrazine-2-carboxamide |
|---|
| Traditional Name | glipizide |
|---|
| SMILES | CC1=CN=C(C=N1)C(O)=NCCC1=CC=C(C=C1)S(=O)(=O)NC(O)=NC1CCCCC1 |
|---|
| InChI Identifier | InChI=1S/C21H27N5O4S/c1-15-13-24-19(14-23-15)20(27)22-12-11-16-7-9-18(10-8-16)31(29,30)26-21(28)25-17-5-3-2-4-6-17/h7-10,13-14,17H,2-6,11-12H2,1H3,(H,22,27)(H2,25,26,28) |
|---|
| InChI Key | InChIKey=ZJJXGWJIGJFDTL-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Benzenoids |
|---|
| Class | Benzene and substituted derivatives |
|---|
| Sub Class | Benzenesulfonamides |
|---|
| Direct Parent | Benzenesulfonamides |
|---|
| Alternative Parents | |
|---|
| Substituents | - Benzenesulfonamide
- Benzenesulfonyl group
- Sulfonylurea
- Pyrazine
- Organic sulfonic acid or derivatives
- Heteroaromatic compound
- Aminosulfonyl compound
- Sulfonyl
- Organosulfonic acid or derivatives
- Carboximidic acid
- Carboximidic acid derivative
- Azacycle
- Organoheterocyclic compound
- Organic 1,3-dipolar compound
- Propargyl-type 1,3-dipolar organic compound
- Organic nitrogen compound
- Hydrocarbon derivative
- Organic oxide
- Organosulfur compound
- Organooxygen compound
- Organonitrogen compound
- Organopnictogen compound
- Organic oxygen compound
- Aromatic heteromonocyclic compound
|
|---|
| Molecular Framework | Aromatic heteromonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Biological Properties |
|---|
| Status | Detected and Not Quantified |
|---|
| Origin | Exogenous |
|---|
| Cellular Locations | |
|---|
| Biofluid Locations | Not Available |
|---|
| Tissue Locations | Not Available |
|---|
| Pathways | Not Available |
|---|
| Applications | |
|---|
| Biological Roles | |
|---|
| Chemical Roles | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Appearance | White powder. |
|---|
| Experimental Properties | | Property | Value |
|---|
| Melting Point | 200-203°C | | Boiling Point | Not Available | | Solubility | 37.2 mg/L | | LogP | 1.91 |
|
|---|
| Predicted Properties | |
|---|
| Spectra |
|---|
| Spectra | | Spectrum Type | Description | Splash Key | Deposition Date | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | splash10-0udj-9433200000-0daa174c6f208f739d92 | 2017-09-01 | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | View Spectrum | | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-qTof , Positive | splash10-014i-0119600000-895a0f8ef34678f1200d | 2017-09-14 | View Spectrum | | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-qTof , Positive | splash10-014i-0009600000-3a2ab7e8e725ab4b2090 | 2017-09-14 | View Spectrum | | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-qTof , Positive | splash10-0v4i-3941000000-57ab7532afaad5f9a2ac | 2017-09-14 | View Spectrum | | LC-MS/MS | LC-MS/MS Spectrum - , positive | splash10-014i-0009600000-3a2ab7e8e725ab4b2090 | 2017-09-14 | View Spectrum | | LC-MS/MS | LC-MS/MS Spectrum - , positive | splash10-00di-0329000000-a6f7044e9dfe397cfcdd | 2017-09-14 | View Spectrum | | LC-MS/MS | LC-MS/MS Spectrum - , positive | splash10-014i-0119600000-895a0f8ef34678f1200d | 2017-09-14 | View Spectrum | | LC-MS/MS | LC-MS/MS Spectrum - , positive | splash10-00di-1429000000-60bdb648d5355af7a75b | 2017-09-14 | View Spectrum | | LC-MS/MS | LC-MS/MS Spectrum - , positive | splash10-0v4i-3941000000-57ab7532afaad5f9a2ac | 2017-09-14 | View Spectrum | | LC-MS/MS | LC-MS/MS Spectrum - 60V, Negative | splash10-00bc-9400000000-e36d6f6a0eb4114e661c | 2021-09-20 | View Spectrum | | LC-MS/MS | LC-MS/MS Spectrum - 45V, Negative | splash10-00di-3900000000-e23bb49f877be3901320 | 2021-09-20 | View Spectrum | | LC-MS/MS | LC-MS/MS Spectrum - 75V, Negative | splash10-004l-9100000000-688c676b3e072ae42071 | 2021-09-20 | View Spectrum | | LC-MS/MS | LC-MS/MS Spectrum - 90V, Negative | splash10-01tc-9100000000-4c0399e69298b606717a | 2021-09-20 | View Spectrum | | LC-MS/MS | LC-MS/MS Spectrum - 30V, Positive | splash10-0gi9-0946000000-e87ed6360a6302adddaf | 2021-09-20 | View Spectrum | | LC-MS/MS | LC-MS/MS Spectrum - 60V, Positive | splash10-0w30-1900000000-b3353b86c5a566797995 | 2021-09-20 | View Spectrum | | LC-MS/MS | LC-MS/MS Spectrum - 90V, Positive | splash10-01tc-9100000000-1058c878e881b259b2e6 | 2021-09-20 | View Spectrum | | LC-MS/MS | LC-MS/MS Spectrum - 45V, Positive | splash10-0gc9-0910000000-97927d7e80b6e6c9c189 | 2021-09-20 | View Spectrum | | LC-MS/MS | LC-MS/MS Spectrum - 30V, Positive | splash10-0gi9-0946000000-1bd55371a0002464d88d | 2021-09-20 | View Spectrum | | LC-MS/MS | LC-MS/MS Spectrum - 45V, Positive | splash10-0gc9-0910000000-4c6c3446c687a5f55469 | 2021-09-20 | View Spectrum | | LC-MS/MS | LC-MS/MS Spectrum - 60V, Positive | splash10-0w30-1900000000-91618f445cb7066cc191 | 2021-09-20 | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-006t-1209300000-c14d0f75f56599ec527f | 2016-08-02 | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-0002-7903000000-63e0326a933897ad8d58 | 2016-08-02 | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-05mk-9700000000-3dea1f33244b9e19e407 | 2016-08-02 | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-0007-5208900000-36b94e0ee176fc17450f | 2016-08-03 | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Negative | splash10-00kb-4529000000-18be67f87a3195a21fff | 2016-08-03 | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Negative | splash10-0007-9310000000-3bae0e1f24a4fc985c6b | 2016-08-03 | View Spectrum |
|
|---|
| Toxicity Profile |
|---|
| Route of Exposure | Oral.
Gastrointestinal absorption is uniform, rapid, and essentially complete. |
|---|
| Mechanism of Toxicity | Sulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin. |
|---|
| Metabolism | Hepatic. The major metabolites of glipizide are products of aromatic hydroxylation and have no hypoglycemic activity. A minor metabolite which accounts for less than 2% of a dose, an acetylaminoethyl benzine derivatives, is reported to have 1/10 to 1/3 as much hypoglycemic activity as the parent compound.
Route of Elimination: The primary metabolites are inactive hydroxylation products and polar conjugates and are excreted mainly in the urine.
Half Life: 2-5 hours |
|---|
| Toxicity Values | The acute oral toxicity was extremely low in all species tested (LD50 greater than 4 g/kg). |
|---|
| Lethal Dose | Not Available |
|---|
| Carcinogenicity (IARC Classification) | No indication of carcinogenicity to humans (not listed by IARC). |
|---|
| Uses/Sources | For use as an adjunct to diet for the control of hyperglycemia and its associated symptomatology in patients with non-insulin-dependent diabetes mellitus (NIDDM; type II), formerly known as maturity-onset diabetes, after an adequate trial of dietary therapy has proved unsatisfactory. |
|---|
| Minimum Risk Level | Not Available |
|---|
| Health Effects | Not Available |
|---|
| Symptoms | The acute oral toxicity was extremely low in all species tested (LD50 greater than 4 g/kg). Overdosage of sulfonylureas including glipizide can produce hypoglycemia. |
|---|
| Treatment | Not Available |
|---|
| Normal Concentrations |
|---|
| Not Available |
|---|
| Abnormal Concentrations |
|---|
| Not Available |
|---|
| External Links |
|---|
| DrugBank ID | DB01067 |
|---|
| HMDB ID | HMDB15200 |
|---|
| PubChem Compound ID | 3478 |
|---|
| ChEMBL ID | CHEMBL1073 |
|---|
| ChemSpider ID | 3359 |
|---|
| KEGG ID | Not Available |
|---|
| UniProt ID | Not Available |
|---|
| OMIM ID | |
|---|
| ChEBI ID | 239286 |
|---|
| BioCyc ID | Not Available |
|---|
| CTD ID | D005913 |
|---|
| Stitch ID | Glipizide |
|---|
| PDB ID | Not Available |
|---|
| ACToR ID | Not Available |
|---|
| Wikipedia Link | Glipizide |
|---|
| References |
|---|
| Synthesis Reference | Suresh Kumar Gidwani, Purushottam Singnurkar, Prashant Kumar Tewari, “Sustained release pharmaceutical composition containing glipizide and method for producing same.” U.S. Patent US6270797, issued February, 2000. |
|---|
| MSDS | Link |
|---|
| General References | - Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M: DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. Epub 2007 Nov 29. [18048412 ]
- Wikipedia. Glipizide. Last Updated 15 May 2009. [Link]
- Drugs.com [Link]
- RxList: The Internet Drug Index (2009). [Link]
- MedTV (2009). Glipizide Overdose. [Link]
- Drugs.com [Link]
|
|---|
| Gene Regulation |
|---|
| Up-Regulated Genes | Not Available |
|---|
| Down-Regulated Genes | Not Available |
|---|